Treatment outcomes of neoadjuvant chemotherapy and transoral robotic surgery in locoregionally advanced laryngopharyngeal carcinoma

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>We aimed to identify the optimal indications of neoadjuvant chemotherapy (NACT) and transoral robotic surgery (TORS) in patients with locoregionally advanced (T3‐4 or N2‐3) head and neck cancer (HNC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 50 patients were included in the study.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>T1 was identified in seven cases, T2 in 19, T3 in 22, and T4 in 2. N0 was identified in nine cases, N1 in 18, N2 in 22, and N3 in 1. There were 25 patients (50%) with complete remission of the primary lesion and 25 patients (50%) with partial remission. On pathologic examination of surgical specimens after neoadjuvant chemotherapy and TORS, 2 patients (4%) had a positive surgical margin, and 48 patients (96%) had a negative margin. Pathologic metastatic lymph nodes (LNs) were not observed in 39 cases (78%), and one metastatic LN was observed in 11 cases (22%). The 3‐year recurrence‐free survival (RFS) of all patients was 85.4%. On multivariate analysis, lymphovascular invasion showed a significant correlation with RFS.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In patients with locoregionally advanced HNC, NACT and TORS achieved favorable oncologic and functional outcomes.</jats:p></jats:sec>